441060-02-2

Basic information

• Product Name: (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine
• Synonyms: (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine
• CAS NO: 441060-02-2
• Molecular Weight: 398.936
• Mol File: 441060-02-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine(441060-02-2)
• EPA Substance Registry System: (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine(441060-02-2)

Safety Data

• Hazardous Substances Data: 441060-02-2(Hazardous Substances Data)

Upstream product

• 50638-46-5 4-bromo-3-chloroanisole 
• 817636-89-8 4-(2-chloro-4-methoxyphenyl)-5-methyl-2H-pyrazol-3-ylamine 
• 441060-95-3 2-(2-chloro-4-methoxyphenyl)-3-oxo-butyronitrile 
• 170737-93-6 2-chloro-4-methoxyphenylacetonitrile 
• 817636-90-1 8-hydroxy-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 
• 817636-91-2 8-chloro-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 
• 616-24-0 3-aminopentane 

Downstream Products

• 817636-93-4 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine tosylate 
• 857262-72-7 3-chloro-4-[8-(1-ethylpropylamino)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-3-yl]-phenol 
• 1338727-99-3 3-[2-chloro-4-(difluoromethoxy)phenyl]-N-(1-ethylpropyl)-2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine 

Relevant articles and documents

6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists

To identify an orally active corticotropin-releasing factor 1 receptor antagonist, a series of 6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives were designed, synthesized and evaluated. An in vitro study followed by in vivo and pharmacokinetic studies of these heterotricyclic compounds led us to the discovery of an orally active CRF1 receptor antagonist. The results of a structure-activity relationship study are presented.